FrancophonIA/ELRC3.0 huggingface dataset:
English: By blocking the receptors to which angiotensin II normally attaches, telmisartan stops the hormone having an effect, allowing the blood vessels to widen.
Estonian: Blokeerides retseptorid, millega angiotensiin II tavaliselt seondub, peatab Telmisartaan hormooni toime ja soodustab veresoonte laienemist.
English: For the prevention of cardiovascular problems, the recommended dose is 80 mg once a day.
Estonian: Kardiovaskulaarsete häirete ennetamiseks on soovituslik annus 80 mg üks kord ööpäevas.
English: It is available as white tablets (round: 20 mg; oval: 40 mg; capsule-shaped: 80 mg).
Estonian: Ravimit turustatakse valgete tablettidena (ümmargused 20 mg, ovaalsed 40 mg, kapslikujulised 80 mg).
English: For the treatment of essential hypertension, the recommended dose of Tolura is 40 mg once a day, but some patients may benefit from using a 20-mg dose.
Estonian: Essentsiaalse hüpertensiooni raviks on soovitatav Tolura annus 40 mg üks kord ööpäevas, kuid mõnele patsiendile võib piisata ka 20 mg annusest.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tolura.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Tolura is a medicine that contains the active substance telmisartan.
Estonian: Tolura on ravim, mis sisaldab toimeainena telmisartaani.
English: Therefore, the CHMP's view was that, as for Micardis, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Micardise korral, on Tolura kasulikkus suurem kui sellega kaasnevad riskid.
English: What are the benefit and risk of Tolura?
Estonian: Milles seisneb Tolura kasulikkus ja mis riskid ravimiga kaasnevad?
English: For more information about treatment with Tolura, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Tolura ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: This document is a summary of the European Public Assessment Report (EPAR) for Tolura.
Estonian: Käesolev dokument on ravimi Tolura Euroopa avaliku hindamisaruande kokkuvõte.
English: Because Tolura is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine's.
Estonian: Et Tolura on geneeriline ravim ja bioekvivalentne võrdlusravimitega, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimitel.
English: Why has Tolura been approved?
Estonian: Miks Tolura heaks kiideti?
English: Tolura is used to treat essential hypertension (high blood pressure) in adults.
Estonian: Tolurat kasutatakse essentsiaalse hüpertensiooni (kõrgvererõhutõve) ravimiseks täiskasvanud patsientidel.
English: The active substance in Tolura, telmisartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Estonian: Tolura toimeaine telmisartaan on angiotensiin II retseptori antagonist, mis blokeerib organismi hormooni angiotensiin II toime.
English: Tolura is a ‘generic medicine'.
Estonian: Tolura on geneeriline ravim.
English: This means that Tolura is similar to a ‘reference medicine' already authorised in the European Union (EU) called Micardis.
Estonian: See tähendab, et Tolura on sarnane võrdlusravimiga Micardis, millel juba on Euroopa Liidus müügiluba.
English: dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide.
Estonian: Kui see ei alanda vererõhku, võib annust suurendada 80 mg-ni või täiendada ravi muu kõrgvererõhuravimiga, näiteks hüdroklorotiasiidiga.
English: The CHMP concluded that, in accordance with EU requirements, Tolura has been shown to have comparable quality and to be bioequivalent to Micardis.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Tolura võrdväärne kvaliteet ja bioekvivalentsus ravimiga Micardis.
English: Because Tolura is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Micardis.
Estonian: Et Tolura on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Tolura bioekvivalentsust võrdlusravimiga Micardis.
English: This allows the blood pressure to drop, reducing the risks associated with high blood pressure, such as having a heart attack.
Estonian: See vähendab vererõhku ja kõrgvererõhuga seotud riske, näiteks infarkti või insuldi riski.
English: What is Tolura?
Estonian: Mis on Tolura?
English: Tolura is also used to prevent cardiovascular problems (problems with the heart and blood vessels) such as heart attacks.
Estonian: Tolurat kasutatakse ka kardiovaskulaarsete (südame-veresoonkonna) häirete, näiteks infarkti või insuldi ennetamiseks.
English: How has Tolura been studied?
Estonian: Kuidas Tolurat uuriti?
English: How is Tolura used?
Estonian: Kuidas Tolurat kasutatakse?
English: How does Tolura work?
Estonian: Kuidas Tolura toimib?
English: What is Tolura used for?
Estonian: Milleks Tolurat kasutatakse?
English: The medicine can only be obtained with a prescription.
Estonian: Tolura on retseptiravim.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Daklinza on 22 August 2014.
Estonian: Euroopa Komisjon andis Daklinza müügiloa, mis kehtib kogu Euroopa Liidus, 22. augustil 2014.
English: The usual dose is 60 mg once a day for 12 or 24 weeks.
Estonian: Soovitatav annus on 60 mg üks kord ööpäevas 12 või 24 nädala jooksul.
English: The full EPAR and risk management plan summary for Daklinza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Daklinza kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What is Daklinza and what is it used for?
Estonian: Mis on Daklinza ja milleks seda kasutatakse?
English: The patients in the study were infected with genotypes 1, 2 or 3 and all received treatment for 12 or 24 weeks.
Estonian: Uuringus osalenud patsiendid olid nakatunud genotüüpidega 1, 2 või 3 ja kõiki raviti kas 12 või 24 nädalat.
English: Other information about Daklinza
Estonian: Muu teave Daklinza kohta
English: Daklinza is available as 30, 60, and 90 mg tablets.
Estonian: Daklinzat turustatakse 30, 60 ja 90 mg tablettidena.
English: What measures are being taken to ensure the safe and effective use of
Estonian: Mis meetmed võetakse, et tagada Daklinza ohutu ja efektiivne kasutamine?
English: Regarding its safety, Daklinza was well tolerated and the side effects were similar to those experienced
Estonian: Ohutuse seisukohast oli Daklinza hästi talutav ja kõrvalnähud sarnanesid nendega, mis esinesid
English: How does Daklinza work?
Estonian: Kuidas Daklinza toimib?
English: This is a summary of the European public assessment report (EPAR) for Daklinza.
Estonian: See on ravimi Daklinza Euroopa avaliku hindamisaruande kokkuvõte.
English: Around 99% of patients with genotype 1 infection (125 out of 126), 96% of patients with genotype 2 infection (25 out of 26) and 89% of patients with genotype 3 infection (16 out of 18) did not show any sign of the virus in their blood 12 weeks after the end of their planned treatment.
Estonian: Patsiente, kellel ei tuvastatud 12 nädalat pärast kavakohase ravi lõppu veres viirust, oli 1. genotüübi infektsiooniga patsientide seas ligikaudu 99% (125 patsienti 126st), 2. genotüübi infektsiooniga patsientide seas 96% (25 patsienti 26st) ja 3. genotüübi infektsiooniga patsientide seas 89% (16
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Daklinza have also been included in the summary of product characteristics and the package leaflet.
Estonian: Daklinza ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: What are the risks associated with Daklinza?
Estonian: Mis riskid Daklinzaga kaasnevad?
English: Most patients had not previously been treated for hepatitis C, though some had genotype 1 infection that was resistant to standard medicines (consisting of either telaprevir or boceprevir - the so-called NS3/4A inhibitors - in combination with peginterferon alfa and ribavirin).
Estonian: Enamik patsiente ei olnud varem C-hepatiidi ravi saanud ja mõnel oli standardravimite (mis sisaldavad kas telapreviiri või botsepreviiri, nn NS3/4A inhibiitoreid, koos alfapeginterferooni ja ribaviriiniga) suhtes resistentne 1.
English: The European Medicines Agency noted that Daklinza used in combination with other medicines was shown to be effective against hepatitis C virus, including in patients with genotype 1 resistant to previous treatment.
Estonian: Euroopa Ravimiamet märkis, et koos teiste ravimitega kasutatud Daklinza osutus C-hepatiidi viiruse vastu efektiivseks, sealhulgas varasemale ravile resistentse 1. genotüübiga patsientidel.
English: Daklinza must not be used together with certain medicines that may reduce the effects of Daklinza.
Estonian: Daklinzat ei tohi kasutada koos teatud ravimitega, mis nõrgendavad Daklinza toimet.
English: Daklinza must be used in combination with other medicines for chronic hepatitis C, such as sofosbuvir, peginterferon alfa and ribavirin.
Estonian: Daklinzat peab kasutama koos teiste kroonilise C-hepatiidi ravimitega, nagu sofosbuviir, alfapeginterferoon ja ribaviriin.
English: It is not intended to provide practical advice on how to use Daklinza.
Estonian: Hindamisaruandes ei anta Daklinza kasutamise praktilisi nõuandeid.
English: For more information on the medicines that should not be taken with Daklinza, see the package leaflet.
Estonian: Lisateave ravimite kohta, mida ei tohi võtta koos Daklinzaga, on pakendi infolehel.
English: For more information about treatment with Daklinza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Daklinzaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Additional studies involving patients with genotypes 4 indicate that Daklinza is also as effective against genotype 4 as it is against genotype 1.
Estonian: 4. genotüübiga patsientide lisauuringud tõendasid, et Daklinza on selle genotüübi suhtes sama efektiivne kui 1. genotüübi suhtes.
English: The Agency therefore concluded that the benefits of Daklinza outweigh its risks and recommended that
Estonian: Amet järeldas seetõttu, et Daklinza kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: By blocking this protein, the medicine stops the hepatitis C virus from multiplying.
Estonian: Selle valgu blokeerimisega peatab ravim C-hepatiidi viiruse paljunemise.
English: The most common side effects reported with Daklinza in combination with sofosbuvir with or without ribavirin are fatigue (tiredness), nausea (feeling sick) and headache.
Estonian: Daklinza kõige sagedamad kõrvalnähud manustamisel koos sofosbuviiriga (kas ribaviriiniga või ilma) on väsimus, iiveldus ja peavalu.
English: Daklinza is an antiviral medicine used in combination with other medicines to treat adults with chronic (long-term) hepatitis C, an infectious disease of the liver caused by the hepatitis C virus.
Estonian: Daklinza on viirusvastane ravim, mida kasutatakse kombinatsioonis muude ravimitega kroonilise (pikaajalise) C-hepatiidi (C-hepatiidi viiruse põhjustatud nakkuslik maksahaigus) raviks täiskasvanutel.
English: Several varieties (genotypes) of hepatitis C virus exist and Daklinza is recommended for use in patients with virus of genotypes 1, 3 and 4.
Estonian: C-hepatiidi viirusel on mitu genotüüpi, Daklinzat soovitatakse kasutada 1., 3. ja 4. genotüübi korral.
English: Almost all the patients in the main study had the virus cleared from their blood.
Estonian: Viirus kadus peaaegu kõigi põhiuuringus osalenud patsientide verest.
English: The combination of medicines to use and the duration of treatment will depend on the genotype of hepatitis C virus the patient is infected with and the nature of the liver problem, for example liver cirrhosis (scarring) or the liver not working well enough.
Estonian: Kasutatavate ravimite kombinatsioon ja ravi kestus sõltuvad nakatunud patsiendi C-hepatiidi viiruse genotüübist ja maksaprobleemide laadist, näiteks kas patsiendil on maksatsirroos (maksakoe sidekoestumine) või maksatalitluse häired.
English: The dose may have to be raised or lowered if the patient is taking other medicines that decrease or increase Daklinza's effects.
Estonian: Kui patsient võtab muid ravimeid, mis nõrgendavad või tugevdavad Daklinza toimet, võib olla vaja annust suurendada või vähendada.
English: For the full list of all side effects reported with Daklinza, see the package leaflet.
Estonian: Daklinza kohta teatatud kõrvalnähtude täielik loetelu on pakendi
English: For practical information about using Daklinza, patients should read the package leaflet or contact their
Estonian: Kui vajate Daklinza kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti
English: The company that markets Daklinza will carry out a study in patients who previously have had liver cancer to evaluate the risk of liver cancer returning after treatment with direct-acting antivirals such as Daklinza.
Estonian: Daklinzat turustav ettevõte teeb nende patsientide uuringu, kel oli maksavähk, et hinnata maksavähi taastumise riski pärast ravi selliste otseste viirusvastaste ravimitega nagu Daklinza, sest on andmeid, et varasema maksavähiga patsientide ravimine nende ravimitega võib tekitada neil vähi kiirema taastumise riski.
English: Daklinza can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in the management of patients with chronic hepatitis C.
Estonian: Daklinza on retseptiravim ning ravi sellega peab alustama ja jälgima kroonilise C-hepatiidi ravis
English: What benefits of Daklinza have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Daklinza kasulikkus?
English: It contains the active substance daclatasvir.
Estonian: Daklinza toimeaine on daklatasviir.
English: The active substance in Daklinza, daclatasvir, blocks the action of a protein in the hepatitis C virus called ‘NS5A', which is essential for the virus to multiply.
Estonian: Daklinza toimeaine daklatasviir blokeerib C-hepatiidi viiruses oleva paljunemiseks olulise valgu NS5A.
English: Daklinza used in combination with sofosbuvir (with or without ribavirin) was effective at clearing the hepatitis C virus from the blood in a main study involving 211 adults.
Estonian: Põhiuuringus (211 täiskasvanud patsienti) oli koos sofosbuviiriga (kas ribaviriiniga või ilma) manustatud Daklinza vere puhastamisel C-hepatiidi viirusest efektiivne.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Lymphoseek on 19 November 2014.
Estonian: Euroopa Komisjon andis Lymphoseeki müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 19. novembril 2014.
English: The full EPAR and risk management plan summary for Lymphoseek can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Lymphoseeki kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Lymphoseek?
Estonian: Mis meetmed võetakse, et tagada Lymphoseeki ohutu ja efektiivne kasutamine?
English: A risk management plan has been developed to ensure that Lymphoseek is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Lymphoseeki võimalikult ohutu kasutamine.
English: Other information about Lymphoseek
Estonian: Muu teave Lymphoseeki kohta
English: What is Lymphoseek and what is it used for?
Estonian: Mis on Lymphoseek ja milleks seda kasutatakse?
English: This helps to decide if further surgery to remove more lymph nodes is needed.
Estonian: See aitab otsustada, kas edasine operatsioon lümfisõlmede eemaldamiseks on vajalik.
English: Other side effects seen were uncommon, mild and short-lived.
Estonian: Muud kõrvalnähud esinesid aeg-ajalt, olid kerged ja lühiajalised.
English: In these two studies, doctors were able to detect a higher number of sentinel lymph nodes with Lymphoseek than with the blue dye: almost all of the lymph nodes identified using the blue dye (98% in one study and 100% in the other) were identified using Lymphoseek, while only around 70% and 60%, respectively, of the lymph nodes detected using Lymphoseek were detected with the blue dye.
Estonian: Nendes kahes uuringus suutsid arstid avastada Lymphoseekiga rohkem valvurlümfisõlmi kui sinise värvainega: peaaegu kõik sinist värvainet kasutades leitud lümfisõlmed (98% ühes uuringus ja 100% teises) tehti kindlaks, kasutades Lymphoseeki, samas kui sinise värvainega tuvastati vastavalt vaid 70% ja 60% Lymphoseekiga leitud lümfisõlmedest.
English: Given the importance of locating lymph nodes in the treatment of cancers and the manageable side effects seen with Lymphoseek, the Committee concluded that its benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Arvestades lümfisõlmede lokaliseerimise tähtsust vähiravis ja Lymphoseeki kasutamisel täheldatud ohjatavaid kõrvalnähte, otsustas inimravimite komitee, et Lymphoseeki kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Why is Lymphoseek approved?
Estonian: Miks Lymphoseek heaks kiideti?
English: A special camera that detects radiation is then used to see where the lymph nodes are and therefore where the cancer is likely to spread.
Estonian: Seejärel kasutatakse spetsiaalset radioaktiivsust tuvastavat kaamerat, et näha, kus lümfisõlmed asuvad ja kuhu vähk seega tõenäoliselt levib.
English: This is a summary of the European public assessment report (EPAR) for Lymphoseek.
Estonian: See on ravimi Lymphoseek Euroopa avaliku hindamisaruande kokkuvõte.
English: The benefits of Lymphoseek were shown in two main studies in which 311 patients with breast or skin cancer had their lymph nodes first mapped with Lymphoseek and then with another method involving the use of a dye known as ‘vital blue dye'.
Estonian: Lymphoseeki kasulikkust näidati kahes põhiuuringus, kus osales 311 rinna- või nahavähiga patsienti, kelle lümfisõlmed kaardistati kõigepealt Lymphoseekiga ja seejärel teise meetodiga, milles kasutatakse sinise vitaalvärviaine nimelist värvainet.
English: Almost all the patients (38 out of 39) with cancerous lymph nodes were identified by Lymphoseek.
Estonian: Peaaegu kõigil patsientidel (38 patsienti 39st), kelle lümfisõlmedesse vähk oli levinud, tehti valvurlümfisõlmed Lymphoseekiga kindlaks.
English: What are the risks associated with Lymphoseek?
Estonian: Mis riskid Lymphoseekiga kaasnevad?
English: It is not intended to provide practical advice on how to use Lymphoseek.
Estonian: Hindamisaruandes ei anta Lymphoseeki kasutamise praktilisi nõuandeid.
English: Because it attaches to these proteins, the radiolabelled medicine builds up in the lymph nodes surrounding the cancer, making them visible with the special camera.
Estonian: Et tilmanotsept kinnitub nimetatud valkudele, koguneb radiomärgistatud ravim vähki ümbritsevates lümfisõlmedes, muutes need erikaamera abil nähtavaks.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Lymphoseek, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Lymphoseeki omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: For practical information about using Lymphoseek, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Lymphoseeki kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Lymphoseek tilmanocept
Estonian: Lymphoseek tilmanotsept
English: Before being injected into the patient, Lymphoseek is ‘radiolabelled', which means that it is tagged with a small amount of radiation.
Estonian: Enne patsiendile manustamist ravim n-ö märgistatakse radioaktiivselt, mis tähendab, et ravimile lisatakse väike annus radioaktiivsust.
English: If the sentinel nodes are found to have no cancer then more extensive lymph nodal surgery can be avoided.
Estonian: Kui valvurlümfisõlmedest vähki ei leita, saab vältida ulatuslikumat lümfisõlmede operatsiooni.
English: In a third study in patients with cancer of the head and neck including mouth cancer, Lymphoseek was used to detect sentinel lymph nodes before patients had their lymph nodes removed surgically.
Estonian: Kolmandas uuringus pea- ja kaelavähi, sealhulgas suuõõnevähiga patsientidel kasutati Lymphoseeki valvurlümfisõlmede avastamiseks, enne kui patsientide lümfisõlmed kirurgiliselt eemaldati.
English: For the full list of all side effects and restrictions with Lymphoseek, see the package leaflet.
Estonian: Lymphoseeki kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: For more information about treatment with Lymphoseek, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Lymphoseekiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The sentinel lymph nodes are the regional lymph nodes where the cancer is likely to spread to first.
Estonian: Valvurlümfisõlmed on regionaalsed lümfisõlmed, kuhu vähk levib tõenäoliselt esimesena.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) noted that studies showed that the use of Lymphoseek led to a higher detection rate for sentinel lymph nodes than the use of vital blue dye.
Estonian: Euroopa Ravimiameti inimravimite komitee märkis, et uuringute kohaselt võimaldas Lymphoseek tuvastada rohkem valvurlümfisõlmi kui sinine vitaalvärvaine.
English: The active substance in Lymphoseek, tilmanocept, attaches to proteins called mannose binding proteins which are found in high amounts in certain immune cells in the lymph nodes.
Estonian: Lymphoseeki toimeaine tilmanotsept kinnitub mannoosi siduvatele valkudele, mida leidub suurel hulgal lümfisõlmede teatud immuunrakkudes.
English: How is Lymphoseek used?
Estonian: Kuidas Lymphoseeki kasutatakse?
English: Lymphoseek is used in patients with breast cancer, melanoma (a skin cancer) and a type of cancer of the mouth known as squamous cell carcinoma.
Estonian: Lymphoseeki kasutatakse rinnavähi, melanoomi (nahavähi liik) ja teatud suuõõnevähi liigi, lamerakulise kartsinoomiga patsientidel.
English: The most common side effects with Lymphoseek seen in clinical studies are pain and irritation at the injection site (seen in less than 1 patient in 100).
Estonian: Lymphoseeki kliinilistes uuringutes täheldatud kõige sagedamad kõrvalnähud (võivad esineda vähem kui 1 patsiendil 100st) on valu ja ärritus süstekohal.
English: Lymphoseek is a solution that is injected either around or inside the cancerous tissue and and is expected to attach to and build up in the nearby lymph nodes.
Estonian: Lymphoseek on lahus, mida süstitakse kas kasvajakoe ümber või sisse ning mis eeldatavasti kinnitub lähedalasuvatele lümfisõlmedele ja koguneb neisse.
English: How does Lymphoseek work?
Estonian: Kuidas Lymphoseek toimib?